- Telehealth Visits
- Insurance plan information
Kanade Shinkai, MD, PhD
Dermatology- Telehealth Visits
- Insurance plan information
Kanade Shinkai, MD, PhD
Dermatology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Kanade Shinkai is a dermatologist with expertise in caring for hospitalized, systemically ill patients. She sees patients with all types of skin disease but specializes in complex conditions, particularly autoimmune and autoinflammatory skin disorders.
In her research, Shinkai studies immunologic and inflammatory skin diseases.
Education & training
Board certification
- Dermatology, American Board of Dermatology
Residency
- Dermatology, UCSF Graduate Medical Education
Internship
- Internal Medicine, UCSF Graduate Medical Education
Degree
- MD, UCSF School of Medicine
My expertise
Specialties
Conditions
- Squamous Cell Carcinoma
- Melanoma
- Hyperhidrosis
- Eczema
- Skin Cancer
- Basal Cell Carcinoma
Locations
My research
Publications
Showing 1-6 of 122 reviews
- February 20, 20265 out of 5 Stars
Dr. Shinkai is a wonderful clinician, attentive, knowledgeable and friendly. I had and I will recommended her to my friend as and family..
- February 17, 20265 out of 5 Stars
My care provider always takes the very best care of me
- February 6, 20265 out of 5 Stars
Dr. Shinkai is an amazing physician. She listens well, is thoughtful about her conclusions and recommendations, and demonstrates considerable compassion.
- February 6, 20265 out of 5 Stars
Dr. Shinkai is a gem. Very thorough, practical and efficient.
- January 29, 20265 out of 5 Stars
I have had many experiences in the dermatology office, and this was the best.
- January 29, 20265 out of 5 Stars
Dr. Shinkai consistently provides excellent medical care In a caring and professional manner. Always.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.